Registry for monitoring small kidney tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects data on patients with small renal masses (≤4cm) to compare the safety and efficacy of active surveillance versus immediate intervention. Patients are enrolled and followed prospectively, with those on active surveillance undergoing regular imaging, blood tests, and quality of life assessments. The goal is to determine if active surveillance is a viable option for managing small kidney tumors without immediate treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.
* Age ≥ 18 and able to read, understand and sign informed consent.
* Must be willing to adhere to the treatment algorithm and time constraints therein.

Exclusion Criteria:

* Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.

Where it's running

• Johns Hopkins Hospital
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Mohamad E Allaf, MD, MBA — Johns Hopkins University
• Study coordinator: Nirmish Singla
• Email: nsingla2@jhmi.edu
• Phone: 410-502-3692

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hyperspectral imaging to guide robot-assisted kidney tumor removal

  Doctors are testing a new imaging method during robotic kidney surgery to see if it helps identify tumor tissue and blood flow in adults with kidney tumors up to 7 cm.

  Recruiting University of Leipzig · Leipzig · NCT07803315

• MRI-based AI to classify and grade renal tumors

  This study tests AI methods on MRI data from adults with kidney tumors to see if they can identify tumor type and grade before surgery.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07743749

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

• Comparing back (SARA) versus side (flank) positions for single-port robotic partial kidney tumor removal.

  This will see if placing adults on their back using the SARA technique or on their side leads to fewer complications and faster recovery for people having single-port robotic partial nephrectomy for small kidney tumors.

  Recruiting Niguarda Hospital · Milan · NCT07234409

• Treating the main kidney tumor in metastatic kidney cancer during immunotherapy

  This trial will see if adding surgery or radiotherapy to the main kidney tumor helps people with metastatic clear‑cell kidney cancer who are already benefiting from anti‑PD1–based therapy live longer.

  Recruiting Phase 4 Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT06903312

• Comparing systemic treatment alone to systemic treatment with added radiotherapy for kidney cancer with few metastases

  This study is testing if adding targeted radiation therapy to regular treatment can help people with kidney cancer that has spread a little to live longer without their cancer getting worse.

  Recruiting Phase 3 Samsung Medical Center · Seoul · NCT06467097

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.